Health
Virus drug benefit only marginal: study – Education – Australian Associated Press
Researchers say a new study of Gilead Sciences’ remdesivir raises questions about the efficacy of the drug in the treatment of COVID-19.
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News23 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business24 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News22 hours agoAfter Hours Gallery Visits, French Dining and Garden Illuminations: Your Guide to the Ultimate Melbourne Culture Fix
-
General20 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change